特丁胺培哚普利(Perindopril Erbumine) - 药物靶点：ACE_在研适应症：心脏病，心脏衰竭，高血压_专利_临床

概要

基本信息

药物类型

小分子化药

别名

perindopril、Perindopril erbumine (JAN/USP)、Perindopril tert-Butylamine

+ [11]

靶点

ACE

作用机制

ACE抑制剂(血管紧张素转化酶抑制剂)

治疗领域

心血管疾病

在研适应症

心脏病心脏衰竭高血压

非在研适应症

粒细胞减少症血管性水肿胶原蛋白疾病+ [6]

原研机构

Servier Pharmaceuticals LLC初创企业

在研机构

Servier Pharmaceuticals LLC初创企业

Daiichi Sankyo Co., Ltd.

Kyowa Kirin Co., Ltd.

+ [1]

非在研机构

Symplmed Pharmaceuticals LLCInstitut de Recherches Intern ServierDaiichi Seiyaku Co., Ltd.

最高研发阶段批准上市

首次获批日期

美国 (1993-12-30),

粒细胞减少症血管性水肿胶原蛋白疾病+ [4]

最高研发阶段(中国)批准上市

特殊审评-

登录后查看首次获批时间轴

结构

分子式C23H43N3O5

InChIKeyIYNMDWMQHSMDDE-MHXJNQAMSA-N

CAS号107133-36-8

关联

74

项与特丁胺培哚普利相关的临床试验

ACTRN12624000648527 / Not yet recruiting临床4期IIT

FAN Trial: A randomised controlled open label trial assessing the effect of perindopril erbumine on Fontan-Associated Nephropathy in adults and children 5 years or older.

开始日期2024-06-01

申办/合作机构-

NCT06341101 / Recruiting临床4期

Timely Recovery After Subclinical Heart Failure (TREASURE Trial)

The goal of this randomized controlled trial is to assess the effectiveness of ACE inhibitors versus standard care) in reversing asymptomatic heart failure (HF stage-B) and/or diastolic dysfunction during a two-year open-label treatment period for formerly preeclamptic women on:
Reversibility of structural and functional myocardial impairment in asymptomatic HF towards healthy values;
The progression from asymptomatic to symptomatic HF (symptoms scored based on the NYHA criteria);
Cardiovascular performance (volume- and pressure load), cardio metabolic risk factors (glucose metabolism, lipid status, kidney function) and quality of life (questionnaires);
Novel biomarkers and relevant microRNA's indicative for hypertrophy, fibrosis inflammation and ischemia.
Eligible subjects will be counselled and upon informed consent randomized for either medication group (n=65) or care as usual group (n=65). After a complete cardiovascular assessment, medication will be initiated open-labeled (Perindopril 2 mg or no medication). Thereafter, standard medical check-ups (blood pressure, ECG, kidney function, transthoracic cardiac ultrasound, endothelial function, quality of life questionnaires, medical history taking, blood and urine banking) will be performed every six months for two years.
Researchers will compare ACE inhibitor (Perindopril 2 mg) and care as usual (i.e. no medication) to investigate whether ACE inhibitor allows timely recovery after subclinical heart failure.

开始日期2024-03-26

申办/合作机构

Academisch Ziekenhuis Maastricht

[+1]

NCT06213610 / Recruiting临床1期

Open-label Randomized Crossover Two Period Single Dose Bioequivalence Study of Two Formulations of Perindopril (Perindopril Tert-butylamine) 8 mg (Pharmtechnology LLC, Republic of Belarus) and Prestarium® A 10 mg (Perindopril Arginine) 10 mg Tablets (Les Laboratoires Servier Industrie, France) in Healthy Volunteers Under Fasting Conditions

This is an open-labeled, randomized, two period, single-center, crossover, comparative study, where each participant will be randomly assigned to the reference (Prestarium ® A 10 mg tablets) or the test (Perindopril 8 mg tablets) formulation in each period of study (sequences Test-Reference (TR) or Reference-Test (RT)), in order to evaluate if both formulations are bioequivalent.

开始日期2024-01-09

申办/合作机构

Pharmtechnology, LLC

100 项与特丁胺培哚普利相关的临床结果

登录后查看更多信息

100 项与特丁胺培哚普利相关的转化医学

登录后查看更多信息

100 项与特丁胺培哚普利相关的专利（医药）

登录后查看更多信息

2,118

项与特丁胺培哚普利相关的文献（医药）

2024-03-01·European journal of pharmacology

Chymase-independent vascular Ang-(1–12)/Ang II pathway and TXA2 generation are involved in endothelial dysfunction in the murine model of heart failure

Article

作者: Garcia-Redondo, Ana B ; Mohaissen, Tasnim ; Wojnar-Lason, Kamila ; Buczek, Elzbieta ; Briones, Ana M ; Bar, Anna ; Kij, Agnieszka ; Marczyk, Brygida ; Chlopicki, Stefan ; Karas, Agnieszka

The angiotensin (Ang)-(1-12)/Ang II pathway contributes to cardiac pathology. However, its involvement in the development of peripheral endothelial dysfunction associated with heart failure (HF) remains unknown. Therefore, this study aimed to characterise the effect of exogenous Ang-(1-12) and its conversion to Ang II on endothelial function using the murine model of HF (Tgαq*44 mice), focusing on the role of chymase and vascular-derived thromboxane A₂ (TXA₂). Ex vivo myographic assessments of isolated aorta showed impaired endothelium-dependent vasodilation in late-stage HF in 12-month-old Tgαq*44 mice. However, endothelium-dependent vasodilation was fully preserved in the early stage of HF in 4-month-old Tgαq*44 mice and 4- and 12-month-old FVB control mice. Ang-(1-12) impaired endothelium-dependent vasodilation in 4- and 12-month-old Tgαq*44 mice, that was associated with increased Ang II production. The chymase inhibitor chymostatin did not inhibit this response. Interestingly, TXA₂ production reflected by TXB₂ measurement was upregulated in response to Ang-(1-12) and Ang II in aortic rings isolated from 12-month-old Tgαq*44 mice but not from 4-month-old Tgαq*44 mice or age-matched FVB mice. Furthermore, in vivo magnetic resonance imaging showed that Ang-(1-12) impaired endothelium-dependent vasodilation in the aorta of Tgαq*44 mice and FVB mice. However, this response was inhibited by angiotensin I converting enzyme (ACE) inhibitor; perindopril, angiotensin II receptor type 1 (AT₁) antagonist; losartan and TXA₂ receptor (TP) antagonist-picotamide in 12-month-old-Tgαq*44 mice only. In conclusion, the chymase-independent vascular Ang-(1-12)/Ang II pathway and subsequent TXA₂ overactivity contribute to systemic endothelial dysfunction in the late stage of HF in Tgαq*44 mice. Therefore, the vascular TXA₂ receptor represents a pharmacotherapeutic target to improve peripheral endothelial dysfunction in chronic HF.

2024-02-01·Hospital pharmacy

Perindopril/Indapamide-Induced Photosensitivity

Article

作者: Denguezli, Mohamed ; Ben Salem, Chaker ; Zayani, Hanen ; Sahnoun, Dhouha ; Slim, Roudha

2024-02-01·Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Effects of telmisartan on metabolic syndrome components: a comprehensive review

Review

作者: Hosseinzadeh, Hossein ; Imenshahidi, Mohsen ; Roohbakhsh, Ali

Telmisartan is an antagonist of the angiotensin II receptor used in the management of hypertension (alone or in combination with other antihypertensive agents. It belongs to the drug class of angiotensin II receptor blockers (ARBs). Among drugs of this class, telmisartan shows particular pharmacologic properties, including a longer half-life than any other angiotensin II receptor blockers that bring higher and persistent antihypertensive activity. In hypertensive patients, telmisartan has superior efficacy than other antihypertensive drugs (losartan, valsartan, ramipril, atenolol, and perindopril) in controlling blood pressure, especially towards the end of the dosing interval. Telmisartan has a partial PPARγ-agonistic effect whilst does not have the safety concerns of full agonists of PPARγ receptors (thiazolidinediones). Moreover, telmisartan has an agonist activity on PPARα and PPARδ receptors and modulates the adipokine levels. Thus, telmisartan could be considered as a suitable alternative option, with multi-benefit for all components of metabolic syndrome including hypertension, diabetes mellitus, obesity, and hyperlipidemia. This review will highlight the role of telmisartan in metabolic syndrome and the main mechanisms of action of telmisartan are discussed and summarized. Many studies have demonstrated the useful properties of telmisartan in the prevention and improving of metabolic syndrome and this well-tolerated drug can be greatly proposed in the treatment of different components of metabolic syndrome. However, larger and long-duration studies are needed to confirm these findings in long-term observational studies and prospective trials and to determine the optimum dose of telmisartan in metabolic syndrome.

23

项与特丁胺培哚普利相关的新闻（医药）

2024-05-07

·米内网

【瞩目】超600亿高血压药市场，江西药企猛攻首仿

精彩内容日前，CDE官网显示，江西施美药业的培哚普利氨氯地平片（Ⅰ）、培哚普利氨氯地平片（Ⅱ）和培哚普利氨氯地平片（Ⅲ）均以仿制4类报产在审。米内网数据显示，米内网数据显示，高血压化药在2023年中国三大终端六大市场销售规模超过600亿元。今年以来，江西施美药业已有6款产品报产在审，其中4款是高血压药。培哚普利氨氯地平片（Ⅰ）、培哚普利氨氯地平片（Ⅱ）和培哚普利氨氯地平片（Ⅲ）均是高血压用药，用于单药治疗不能充分控制高血压的成人患者；或者作为替代疗法适用于在相同剂量水平的培哚普利和氨氯地平联合治疗下病情得以控制的原发性高血压。高血压化药在2023年中国三大终端六大市场销售规模超过600亿元，其中，院内市场（公立医院终端+公立基层医疗终端）是主力销售渠道。培哚普利氨氯地平片（Ⅰ）等3个产品批文情况来源：米内网中国上市药品（MID）数据库米内网数据显示，培哚普利氨氯地平片（Ⅰ）、培哚普利氨氯地平片（Ⅱ）和培哚普利氨氯地平片（Ⅲ）仅有施维雅1家拥有生产批文，培哚普利氨氯地平片（Ⅰ）有山西同达药业、天津力生制药等6家报产在审，培哚普利氨氯地平片（Ⅱ）仅有江西施美药业报产在审，而培哚普利氨氯地平片（Ⅲ）竞争最激烈，有成都硕德药业、江苏万高药业等12家报产在审。值得一提的是，江西施美药业是唯一一家3个品种报产在审的国内企业。江西施美药业今年以来报产在审产品情况来源：米内网中国申报进度（MED）数据库今年以来，江西施美药业已有6款产品报产在审，其中4款是高血压药。截至目前，江西施美药业在高血压化药领域已有11款产品报产在审，培哚普利氨氯地平片（Ⅱ）、坎地沙坦酯氢氯噻嗪片、厄贝沙坦氨氯地平片（Ⅰ）、替米沙坦氨氯地平片等均有望拿下国内首仿。资料来源：CDE官网、米内网数据库等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

2024-02-21

·BioSpace

Discover this new generic drug in the PERINDOPRIL range

MONTREAL, Feb. 21, 2024 /CNW/ - Pharmascience Canada is proud to announce the launch of pms-PERINDOPRIL-AMLODIPINE (perindopril arginine and amlodipine), a drug indicated for the treatment of mild to moderate essential hypertension in adults aged 18 to 65 for whom combination therapy is appropriate. This oral treatment contains two medicines, perindopril arginine and amlodipine. They work together to control the blood pressure. pms-PERINDOPRIL-AMLODIPINE are available in bottles of 100 tablets and comes in the following dosage forms: 3.5 mg / 2.5 mg (this treatment is indicated for initial therapy in patients with mild to moderate essential hypertension.) 7 mg / 5 mg 14 mg / 10 mg This medication is a generic equivalent of Viacoram MD1. pms-PERINDOPRIL-AMLODIPINE tablets are available at affordable prices. « We are excited to introduce Perindopril Amlodipine to the Canadian market, as it reflects our mission to improve the health and quality of life of Canadians through innovative and high-quality products, » said Mike Dutton, Vice-President and General Manager of Pharmascience Canada. « Perindopril Amlodipine is manufactured in our Canadian facility which is another example of how we leverage our expertise and capabilities to deliver value to our customers and patients. » ABOUT PHARMASCIENCE INC. Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with 1,500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 50 countries. Ranked 50th among Canada's top 100 Research & Development (R&D) investors in 2022, with 40-50 million dollars invested each year, Pharmascience Inc. is among the largest drug manufacturers in Canada. Pharmascience Inc. has strong values based on the importance of investing in its employees and young people. Through various programs and initiatives, the company ensures it supports their personal development and life. In 2024, the company was awarded Great Place to Work certification for the third year running. PRVIACORAM®1 is a registered trademark owned by Servier Canada Inc. For product information, please contact Pharmascience's Medical Information Department at 1-888-550-6060. SOURCE Pharmascience Inc.

上市批准

2024-02-08

·药渡

这款独家国产仿制降压药首家过评，在等级医院占据9成市场

近日国家药监局官网信息显示，昆山龙灯瑞迪制药的雷米普利片补充申请获批，通过一致性评价，为国内首家过评。事实上，在国内雷米普利片市场中，昆山龙灯瑞迪制药也是目前唯一的国产仿制药玩家。据中康开思数据显示，雷米普利片在2022年等级医院销售为1.11亿元，其中昆山龙灯瑞迪制药占据超9成市场份额；在2022年零售渠道销售为3700万元，其中昆山龙灯瑞迪制药也占据7成以上的市场份额。全国等级医院雷米普利片品牌表现来源：中康开思全国零售渠道雷米普利片品牌表现来源：中康开思据了解，雷米普利的原研企业为德国Hoechst AG，后被赛诺菲收购，1989年首次在法国上市，1991年获美国FDA批准上市，商品名Triatec（瑞泰）。其早在2001年底就获得我国药监局批准上市，而随后昆山龙灯瑞迪制药的雷米普利片仿制药（瑞素坦）在2003年获批上市后，占据了国内的大部分市场份额。目前我国临床常用的降压药一共有5大类，主要是钙通道阻滞剂（CCB）、血管紧张素受体阻滞剂（ARB）、血管紧张素转换酶抑制剂（ACEI）、β受体阻滞剂、利尿剂及以上药物组成的单片复方制剂（SPC）。其中，雷米普利就属于血管紧张素转换酶抑制剂，而这类降压药物在国内销售排名靠前的分别是贝那普利、培哚普利、依那普利等。另据中康开思数据显示，自贝那普利、培哚普利、依那普利陆续入集采后，它们在等级医院的市场销售额逐年下降。比如，贝那普利片就从2018年等级医院的超7亿元，一路下滑至2022年的2亿元。全国等级医院贝那普利片市场来源：中康开思而雷米普利片由于在国内仅昆山龙灯瑞迪制药1家仿制，可以不用担心集采问题，并且目前还没有其他企业报产仿制药，所以此次过评后市场有望得到进一步提升。02高血压患者自我诊疗特征明显降压药市场潜力巨大此外，随着我国人口老龄化加剧以及人们生活习惯改变，高血压已经跃升为各种慢性疾病之首，可以预见的是我国降压药市场潜力巨大。据世界卫生组织的报告显示，2019年中国成人高血压患病率低于全球平均水平，处于较低水平，得益于我国对食盐含钠标准的限制以及高血压管理指南的建立。与此同时，我国高血压患者的用药习惯有明显的自我诊疗特征。受卫生健康公益活动、社区测血压服务、家用血压计等高血压患教活动的普及，越来越多的患者能够在较早期发现高血压，普通患者往往选择自主购买降压药，待高血压进展为心血管疾病等其他更加严重的疾病时，才前往医院就诊。因此，高血压用药在药店渠道和医院渠道的销售表现逐渐发生变化，零售药店市场的销售额情况开始优于医院市场。2022年高血压用药在医院市场销售额达到258.3亿元，较2021年下滑8.1%；在零售药店市场销售额达到281.2亿元，较2021年下滑0.1%。从市场份额看，2021年起，高血压药物在零售药店市场的份额占比超过医院市场，2023年上半年零售药店销售占比达到52.8%。2017-2023H1高血压用药在零售药店和医院市场所占份额来源：中康开思系统免责声明“药渡”公众号所转载该篇文章来源于其他公众号平台，主要目的在于分享行业相关知识，传递当前最新资讯。图片、文章版权均属于原作者所有，如有侵权，请及时告知，我们会在24小时内删除相关信息。微信公众号的推送规则又双叒叕改啦，如果您不点个“在看”或者没设为"星标"，我们可能就消散在茫茫文海之中~点这里，千万不要错过药渡的最新消息哦！

上市批准一致性评价医药出海带量采购

100 项与特丁胺培哚普利相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00624	特丁胺培哚普利	C09AA04	DB00790

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
心脏病	日本	Daiichi Sankyo Co., Ltd.	2005-09-28
心脏衰竭	加拿大	Servier Pharmaceuticals LLC初创企业	1994-12-31
高血压	加拿大	Servier Pharmaceuticals LLC初创企业	1994-12-31
粒细胞减少症	美国	Symplmed Pharmaceuticals LLC	1993-12-30
血管性水肿	美国	Symplmed Pharmaceuticals LLC	1993-12-30
胶原蛋白疾病	美国	Symplmed Pharmaceuticals LLC	1993-12-30
冠心病	美国	Symplmed Pharmaceuticals LLC	1993-12-30
原发性高血压	美国	Symplmed Pharmaceuticals LLC	1993-12-30
心肌梗塞	美国	Symplmed Pharmaceuticals LLC	1993-12-30
肾功能不全	美国	Symplmed Pharmaceuticals LLC	1993-12-30

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
糖尿病	临床3期	加拿大	Servier Pharmaceuticals LLC初创企业	2010-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESC2023	临床3期	原发性高血压	532	Perindopril arginine 5 mg/Indapamide 1.25 mg/Amlodipine 5 mg (P5/I1.25/A5)	夢繭鑰遞蓋網夢窪衊醖(憲衊壓積窪壓襯遞齋鏇) = 鑰獵繭艱壓鏇鏇憲廠鬱糧壓糧壓簾餘窪簾築艱 (簾齋願蓋餘製鬱願鹹鬱 ) 更多	积极	2023-08-27
				Perindopril tert-butylamine 4 mg/Indapamide 1.25 mg (P4/I1.25) plus Amlodipine 5 mg (P4/I1.25 +A5)	鏇艱餘衊鏇繭齋範廠憲(夢繭壓鬱顧積製醖顧遞) = 範壓齋鹽淵膚網襯衊糧淵鑰鹽獵鹹艱遞鏇鬱淵 (鑰築獵淵餘範繭憲壓蓋 ) 更多
ESC2023	N/A	一线	-	Perindopril-based regimens	壓淵構齋鹹廠簾網鬱鏇(積餘網築築願膚獵夢遞) = 糧壓壓糧遞夢夢窪觸糧積衊餘選糧鏇餘鏇窪願 (壓膚繭顧繭顧製鏇鏇築, 87–8973)	-	2023-08-27
				Losartan-based regimens	壓淵構齋鹹廠簾網鬱鏇(積餘網築築願膚獵夢遞) = 膚鏇窪鹹築夢夢顧獵鹽積衊餘選糧鏇餘鏇窪願 (壓膚繭顧繭顧製鏇鏇築, 104–9365)
ESC2022	N/A	高血压二线	-	Perindopril/amlodipine+indapamide	築夢鑰襯淵膚窪壓壓膚(選憲廠襯範繭夢鑰築窪) = 11 adverse reactions 鏇鹽廠壓遞憲淵餘鏇網 (構鬱鏇夢憲遞齋夢顧鹹 )	-	2022-04-07
ISRCTN67799751 (Pubmed \| Adv Ther)	N/A	高血压	22	Perindopril arginine/indapamide single-pill combination (Pa/I SPC)	衊願醖願夢蓋廠鬱製膚(簾築夢窪願簾繭壓鬱鹹) = 淵遞範鏇積衊積顧構窪鑰鹽簾艱簾壓簾簾夢餘 (襯顧築襯憲遞範鹹夢構 ) 更多	-	2020-12-01
ESC2019	N/A	慢性心力衰竭 metalloproteinase-9 (MMP-9) \| tissue inhibitor of metalloproteinase 1 (TIMP-1) \| E-selectin ... 更多	30	Perindopril A 5 mg/day	遞糧鹹鑰鏇窪願築鹹糧(選衊構餘蓋積觸觸壓網) = 簾觸齋壓醖鏇鹹衊蓋夢艱鑰糧鏇構簾齋膚廠廠 (網壓醖網鬱製網簾糧觸 ) 更多	-	2019-05-27
				Perindopril A 10 mg/day	遞糧鹹鑰鏇窪願築鹹糧(選衊構餘蓋積觸觸壓網) = 獵壓構鹽糧網艱夢壓範艱鑰糧鏇構簾齋膚廠廠 (網壓醖網鬱製網簾糧觸 ) 更多
ESC2018	N/A	高血压	796	Perindopril/indapamide/amlodipine fixed-dose combination	網製衊顧淵鏇構製廠築(鬱鹽醖糧淵憲願繭製膚) = 廠願糧網鏇構淵衊壓壓蓋夢衊遞遞憲顧糧窪顧 (窪遞憲鬱壓襯構觸鏇簾 ) 更多	-	2018-08-26
NCT01669434 (CTgov)	临床4期	低血压	291	LISINOPRIL+Captopril+ENALAPRILAT+BENAZEPRIL HYDROCHLORIDE+PERINDOPRIL ERBUMINE+RAMIPRIL+QUINAPRIL HYDROCHLORIDE+Enalapril Maleate+Perindopril Arginine+FOSINOPRIL SODIUM+TRANDOLAPRIL+MOEXIPRIL HYDROCHLORIDE (ACEI Omission)	積夢鑰願醖鹽範範鹽餘(築鏇壓網憲築壓獵鬱憲) = 廠鹽選艱襯遞齋鬱糧夢憲願蓋鏇網艱選願繭襯 (鑰簾醖遞簾齋願膚築築, 製願艱構鹹獵襯築繭齋 ~ 鑰遞鏇範蓋夢顧糧襯襯) 更多	-	2017-12-11
				ACEI continuation (ACEI Continuation)	積夢鑰願醖鹽範範鹽餘(築鏇壓網憲築壓獵鬱憲) = 遞繭觸願觸夢窪憲構廠憲願蓋鏇網艱選願繭襯 (鑰簾醖遞簾齋願膚築築, 範範遞獵築窪遞築壓蓋 ~ 艱選鏇鹹鏇網積鹽蓋窪) 更多
ESC2017	N/A	高血压	-	Perindopril+Atorvastatin	憲壓夢構鏇餘壓壓蓋壓(網憲選齋繭壓膚積製膚) = 4.5% of patients 夢築淵顧願憲範窪願構 (糧壓餘蓋壓淵遞膚鑰鏇 ) 更多	-	2017-08-26
ESC2016	N/A	血管疾病	-	Perindopril on top of β-blocker	膚鏇觸窪窪鹽糧獵壓顧(膚窪鏇憲窪製鹹淵鹽積) = 積衊膚範簾醖醖製窪窪築鹹膚齋糧製簾鹽餘廠 (壓齋遞餘鏇衊蓋齋憲憲 )	积极	2016-08-28
				Perindopril without β-blocker	膚鏇觸窪窪鹽糧獵壓顧(膚窪鏇憲窪製鹹淵鹽積) = 網鬱顧鹹鬱衊遞遞築鹽築鹹膚齋糧製簾鹽餘廠 (壓齋遞餘鏇衊蓋齋憲憲 )
ESC2016	N/A	高血压	-	Free combination of perindopril and amlodipine	壓餘顧糧願鑰壓構艱遞(鑰廠築膚醖醖鏇鏇鹽壓) = 鑰觸齋網襯積鹽壓鹹齋簾衊艱築繭網願鹽願窪 (蓋積願淵膚鏇艱鏇鹽衊 )	-	2016-08-28
				Fixed dose combination of perindopril and amlodipine	壓餘顧糧願鑰壓構艱遞(鑰廠築膚醖醖鏇鏇鹽壓) = 鬱糧積鑰網壓窪衊網鑰簾衊艱築繭網願鹽願窪 (蓋積願淵膚鏇艱鏇鹽衊 )